BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 25841623)

  • 1. Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients.
    Arvold ND; Tanguturi SK; Aizer AA; Wen PY; Reardon DA; Lee EQ; Nayak L; Christianson LW; Horvath MC; Dunn IF; Golby AJ; Johnson MD; Claus EB; Chiocca EA; Ligon KL; Alexander BM
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):384-9. PubMed ID: 25841623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypofractionated radiation therapy versus standard fractionated radiation therapy with concurrent temozolomide in elderly patients with newly diagnosed glioblastoma.
    Wang TJC; Wu CC; Jani A; Estrada J; Ung T; Chow DS; Soun JE; Saad S; Qureshi YH; Gartrell R; Saadatmand HJ; Saraf A; Garrett MD; Grubb C; Isaacson SR; Cheng SK; Sisti MB; Bruce JN; Sheth SA; Lassman AB; Iwamoto FM; McKhann GM
    Pract Radiat Oncol; 2016; 6(5):306-314. PubMed ID: 26952813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis.
    Minniti G; Scaringi C; Lanzetta G; Terrenato I; Esposito V; Arcella A; Pace A; Giangaspero F; Bozzao A; Enrici RM
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):109-15. PubMed ID: 25442339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interim Results of a Phase II Study of Hypofractionated Radiotherapy with Concurrent Temozolomide Followed by Adjuvant Temozolomide in Patients over 70 Years Old with Newly Diagnosed Glioblastoma.
    Yusuf M; Ugiliweneza B; Amsbaugh M; Boakye M; Williams B; Nelson M; Hattab EM; Woo S; Burton E
    Oncology; 2018; 95(1):39-42. PubMed ID: 29694955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypofractionated versus standard radiation therapy in combination with temozolomide for glioblastoma in the elderly: a meta-analysis.
    Lu VM; Kerezoudis P; Brown DA; Burns TC; Quinones-Hinojosa A; Chaichana KL
    J Neurooncol; 2019 Jun; 143(2):177-185. PubMed ID: 30919157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elderly patients with glioblastoma multiforme treated with concurrent temozolomide and standard- versus abbreviated-course radiotherapy.
    Chang-Halpenny CN; Yeh J; Lien WW
    Perm J; 2015; 19(1):15-20. PubMed ID: 25663202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiation therapy dose escalation for glioblastoma multiforme in the era of temozolomide.
    Badiyan SN; Markovina S; Simpson JR; Robinson CG; DeWees T; Tran DD; Linette G; Jalalizadeh R; Dacey R; Rich KM; Chicoine MR; Dowling JL; Leuthardt EC; Zipfel GJ; Kim AH; Huang J
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):877-85. PubMed ID: 25257812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma.
    Iuchi T; Hatano K; Kodama T; Sakaida T; Yokoi S; Kawasaki K; Hasegawa Y; Hara R
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):793-800. PubMed ID: 24495592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
    Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
    Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness of radiotherapy with vs. without temozolomide in older patients with glioblastoma.
    Arvold ND; Cefalu M; Wang Y; Zigler C; Schrag D; Dominici F
    J Neurooncol; 2017 Jan; 131(2):301-311. PubMed ID: 27770280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience.
    Cao JQ; Fisher BJ; Bauman GS; Megyesi JF; Watling CJ; Macdonald DR
    J Neurooncol; 2012 Apr; 107(2):395-405. PubMed ID: 22105851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.
    Malmström A; Grønberg BH; Marosi C; Stupp R; Frappaz D; Schultz H; Abacioglu U; Tavelin B; Lhermitte B; Hegi ME; Rosell J; Henriksson R;
    Lancet Oncol; 2012 Sep; 13(9):916-26. PubMed ID: 22877848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Standard dose and dose-escalated radiation therapy are associated with favorable survival in select elderly patients with newly diagnosed glioblastoma.
    Jackson WC; Tsien CI; Junck L; Leung D; Hervey-Jumper S; Orringer D; Heth J; Wahl DR; Spratt DE; Cao Y; Lawrence TS; Kim MM
    J Neurooncol; 2018 May; 138(1):155-162. PubMed ID: 29388034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival Outcomes of Elderly Patients With Glioblastoma Multiforme in Their 75th Year or Older Treated With Adjuvant Therapy.
    Harris G; Jayamanne D; Wheeler H; Gzell C; Kastelan M; Schembri G; Brazier D; Cook R; Parkinson J; Khasraw M; Louw S; Back M
    Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):802-810. PubMed ID: 28602411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma.
    Kocher M; Frommolt P; Borberg SK; Rühl U; Steingräber M; Niewald M; Staar S; Stuschke M; Becker G; Fischedick AR; Herfarth K; Grauthoff H; Müller RP
    Strahlenther Onkol; 2008 Nov; 184(11):572-9. PubMed ID: 19016015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.
    Chen C; Damek D; Gaspar LE; Waziri A; Lillehei K; Kleinschmidt-DeMasters BK; Robischon M; Stuhr K; Rusthoven KE; Kavanagh BD
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1066-74. PubMed ID: 20932651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis.
    Panet-Raymond V; Souhami L; Roberge D; Kavan P; Shakibnia L; Muanza T; Lambert C; Leblanc R; Del Maestro R; Guiot MC; Shenouda G
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):473-8. PubMed ID: 18554821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma.
    Gerstein J; Franz K; Steinbach JP; Seifert V; Fraunholz I; Weiss C; Rödel C
    Radiother Oncol; 2010 Dec; 97(3):382-6. PubMed ID: 20850883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
    Reddy K; Damek D; Gaspar LE; Ney D; Waziri A; Lillehei K; Stuhr K; Kavanagh BD; Chen C
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):655-60. PubMed ID: 22483738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.